Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema...
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a...
– 35% CR rate (7/20) among patients with relapsed/refractory NPM1-mutant AML treated at 600 mg dose (RP2D) – – 33%...
OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month...
Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules)...
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no...
7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion...
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment...
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among...